Browsing Tag
Phase 2b trial
3 posts
Nektar Therapeutics (NASDAQ: NKTR) rezpegaldesleukin shows dual action in skin and asthma — is this a pipeline turning point?
Nektar Therapeutics’ rezpegaldesleukin delivers dual efficacy in dermatitis and asthma in Phase 2b REZOLVE-AD trial. See how this Treg-based therapy is changing the game.
AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic…
Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure
Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after…